[ASCO] Clinical significance ofEGFRamplification in patients withEGFR-mutated metastatic non–small cell lung cancer receiving first-line osimertinib.

 关闭 求助已关闭
嗦了蜜 发表于 2026-7-17 10:02:57 | 显示全部楼层 |阅读模式
悬赏20积分

本帖最后由 嗦了蜜 于 2026-7-17 15:51 编辑

期刊:Journal of Clinical Oncology

文献作者:Alessandro Di Federico; Federica Pecci; Mark Yungjie Jeng; Marianna Peroni; Daniele Marinelli; Alessandro Leonetti; Francesco Mantuano; Roberta Minari; Stefano Scalera; Laura Cipriani; Marcello Maugeri-Saccà; Nicola Calonaci; Giulio Caravagna; Biagio Ricciuti; Mark M. Awad; Federico Cappuzzo; Marcello Tiseo; Helena Alexandra Yu; Pasi A. Janne; Andrea Ardizzoni

出版日期:2026-6-1

DOI号:10.1200/jco.2026.44.16_suppl.8643

下载链接:https://ascopubs.org/doi/pdfdire ... 26.44.16_suppl.8643

文献链接:https://doi.org/10.1200/jco.2026.44.16_suppl.8643

当前文献来源于 American Society of Clinical Oncology (ASCO)


备注信息:
全部回复0 显示全部楼层

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

返回列表